ILMN — Illumina, Inc.
$207.01
$-2.54 (-1.21%)
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Market Cap
$31.30B
Forward P/E
33.5x
52-Week Range
N/A
ILMN Price History
Revenue vs. Net Income
$4.3B
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$931M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
23.5%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.7x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
3.4%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-1.9%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
